Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma
Theodoros P. Vassilakopoulos(National and Kapodistrian University of Athens), Gerassimos A. Pangalis(Athens Medical Center), Thymios Michalopoulos(Hygeia Hospital), Panayiotis Panayiotidis(National and Kapodistrian University of Athens), Eleni Variamis(National and Kapodistrian University of Athens), Panayiotis Tsaftaridis, Konstantinos Anargyrou(Laiko General Hospital of Athens), Christos Karkantaris(Laiko General Hospital of Athens), Styliani Kokoris(University General Hospital Attikon), Marina P. Siakantaris(National and Kapodistrian University of Athens), Maria K. Angelopoulou(Laiko General Hospital of Athens), Maria Dimopoulou(National and Kapodistrian University of Athens), Marie Christine Kyrtsonis(National and Kapodistrian University of Athens), Flora N. Kontopidou(Laiko General Hospital of Athens), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Dimitrios Boutsis(National and Kapodistrian University of Athens), Constantinos Papavassiliou(Hygeia Hospital)
Cited by 24
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k
Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
|Science|1993|914
The complex role of tumor-infiltrating macrophages
|Nature Immunology|2022|859